AI assistant
BIO-TECHNE Corp — Director's Dealing 2021
Sep 24, 2021
30718_dirs_2021-09-24_842210a7-268a-4e36-88fc-91cc16ef44d6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2021-09-22
Reporting Person: Kelderman Kim (Pres. Diagnostics & Genom)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-09-22 | Common Stock | S | 822 | $529.04 | Disposed | 0 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Options (Right to Buy) | $150.78 | 2025-05-01 | Common Stock (2652) | 2652 | Direct |
| Stock Options (Right to Buy) | $150.78 | 2025-05-01 | Common Stock (7348) | 7348 | Direct |
| Stock Options (Right to Buy) | $177.32 | 2025-08-08 | Common Stock (12044) | 12044 | Direct |
| Stock Options (Right to Buy) | $177.32 | 2025-08-08 | Common Stock (9033) | 9033 | Direct |
| Restricted Stock Units | $ | Common Stock (2363) | 2363 | Direct | |
| Stock Options (Right to Buy) | $190.41 | 2026-08-07 | Common Stock (11961) | 11961 | Direct |
| Stock Options (Right to Buy) | $190.41 | 2026-08-07 | Common Stock (15948) | 15948 | Direct |
| Restricted Stock Units | $ | Common Stock (2015) | 2015 | Direct | |
| Stock Options (Right to Buy) | $267.87 | 2027-08-05 | Common Stock (8991) | 8991 | Direct |
| Stock Options (Right to Buy) | $267.87 | 2027-08-05 | Common Stock (11988) | 11988 | Direct |
| Stock Options (Right to Buy) | $267.87 | 2027-08-05 | Common Stock (8325) | 8325 | Direct |
| Stock Options (Right to Buy) | $267.87 | 2027-08-05 | Common Stock (8325) | 8325 | Direct |
| Restricted Stock Units | $ | Common Stock (1245) | 1245 | Direct | |
| Stock Options (Right to Buy) | $481.82 | 2028-08-06 | Common Stock (4864) | 4864 | Direct |
| Stock Options (Right to Buy) | $481.82 | 2028-08-06 | Common Stock (6486) | 6486 | Direct |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021.
F2: Options to purchase 663 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022.
F3: Options to purchase 1,837 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022.
F4: Options to purchase 3,011 shares vest on each of 8/8/2019, 8/8/2020, 8/8/2021 and 8/8/2022.
F5: Fully exercisable.
F6: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F7: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F8: Options to purchase 3,987 shares vest on each of 8/7/2020, 8/7/2021, 8/7/2022 and 8/7/2023.
F9: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F10: Options to purchase 2,997 shares vest on each of 8/5/2021, 8/5/2022, 8/5/2023 and 8/5/2024.
F11: Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.
F12: Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.
F13: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F14: Options to purchase 1,621 shares vest on each of 8/6/2022 and 8/6/2023 and options to purchase 1,622 shares vest on each of 8/6/2024 and 8/6/2025.